April 10, 2012 9:39 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Brean Murray Carret lowers its rating on Allos Therapeutics (NASDAQ: ALTH) following a definite acquisition agreement with Spectrum. The price target of $2.50 is discontinued.Brean Murray Carret says, "The boards of directors for both Spectrum and Allos have entered into a definitive acquisition agreement. We believe Spectrum is getting Allos for a ‘song' as a result of desperation following the disappointing launch of Folotyn and the failed merger with AMAG last year. Spectrum has an established oncology program with Zevalin, and we believe leveraging the existing sales relationships will greatly increase the market potential for Folotyn. We see Allos as a good strategic fit for Spectrum and foresee no reason for this merger not to proceed. However, we believe the stock is currently reflecting a high probability that this acquisition goes through and do not see additional upside from investment."ALTH closed at $1.82 yesterday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.